0001104659-23-129259.txt : 20231226 0001104659-23-129259.hdr.sgml : 20231226 20231226171001 ACCESSION NUMBER: 0001104659-23-129259 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20231226 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231226 DATE AS OF CHANGE: 20231226 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SomaLogic, Inc. CENTRAL INDEX KEY: 0001837412 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 854298912 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40090 FILM NUMBER: 231513977 BUSINESS ADDRESS: STREET 1: C/O SOMALOGIC, INC. STREET 2: 2945 WILDERNESS PLACE CITY: BOULDER STATE: CO ZIP: 80301 BUSINESS PHONE: (303) 625-9000 MAIL ADDRESS: STREET 1: C/O SOMALOGIC, INC. STREET 2: 2945 WILDERNESS PLACE CITY: BOULDER STATE: CO ZIP: 80301 FORMER COMPANY: FORMER CONFORMED NAME: CM Life Sciences II Inc. DATE OF NAME CHANGE: 20201221 8-K 1 tm2333732d1_8k.htm FORM 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 26, 2023

SomaLogic, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-40090		85-4298912
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

2945 Wilderness Place, Boulder, Colorado		80301
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (303) 625-9000

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

x	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.0001 per share	SLGC	The NASDAQ Stock Market LLC
Warrants, each exercisable for one share of Common Stock at an exercise price of $11.50 per share	SLGCW	The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 7.01

Regulation FD Disclosure.

On December 26, 2023, SomaLogic, Inc., a Delaware corporation (“SomaLogic”), issued a press release, a copy of which is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release, dated as of December 26, 2023.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

Additional Information and Where to Find It

As previously disclosed, on October 4, 2023, SomaLogic, Standard BioTools Inc., a Delaware corporation (“Standard BioTools”), and Martis Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Standard BioTools (“Merger Sub”), entered into an Agreement and Plan of Merger, pursuant to which, among other matters, Merger Sub will merge with and into SomaLogic (the “Merger”), with SomaLogic surviving the Merger as a wholly owned subsidiary of Standard BioTools. In connection with the Merger and required stockholder approval, Standard BioTools filed with the Form S-4, which was declared effective by the Securities and Exchange Commission (the “SEC”) on December 1, 2023. The Form S-4 includes a definitive joint proxy statement of Standard BioTools and SomaLogic and also constitutes a final prospectus of Standard BioTools. The definitive joint proxy statement was mailed or otherwise made available to stockholders of Standard BioTools and SomaLogic on or about December 4, 2023. Standard BioTools’ and SomaLogic’s stockholders are urged to carefully read the joint proxy statement/prospectus (including all amendments, supplements and any documents incorporated by reference therein) and other relevant materials filed or to be filed with the SEC and in their entirety because they contain important information about the Merger and the parties to the Merger. Investors and stockholders may obtain free copies of these documents and other documents filed with the SEC at its website at http://www.sec.gov. In addition, investors may obtain free copies of the documents filed with the SEC by Standard BioTools at http://investors.standardbio.com or contacting Standard BioTools’ Investor Relations department at investors@standardbio.com or at https://investors.somalogic.com or by contacting SomaLogic Investor Relations at investors@somalogic.com.

Participants in the Solicitation

Standard BioTools, SomaLogic and each of their respective executive officers and directors may be deemed to be participants in the solicitation of proxies from SomaLogic’s stockholders with respect to the Merger. Information about Standard BioTools’ directors and executive officers, including their ownership of Standard BioTools’ securities, is set forth in the joint proxy statement/prospectus, Standard BioTools’ proxy statement for its 2023 Annual Meeting of Stockholders, which was filed with the SEC on April 28, 2023, Current Reports on Form 8-K, which were filed with the SEC on May 3, 2023, May 15, 2023, June 16, 2023 and July 28, 2023, and Standard BioTools’ other filings with the SEC. Information concerning SomaLogic’s directors and executive officers, including their ownership of SomaLogic securities, is set forth in the joint proxy statement/prospectus, SomaLogic’s proxy statement for its 2023 Annual Meeting of Stockholders, which was filed with the SEC on April 25, 2023, Current Reports on Form 8-K, which were filed with the SEC on June 6, 2023, as amended on June 14, 2023, June 9, 2023, October 4, 2023 and December 12, 2023, and SomaLogic’s other filings with the SEC. Investors may obtain more detailed information regarding the direct and indirect interests of Standard BioTools and its respective executive officers and directors in the Merger, which may be different than those of Standard BioTools’ stockholders generally, by reading the definitive proxy statements regarding the Merger, which have been filed with the SEC. These documents are available free of charge at the SEC’s website at www.sec.gov, at http://investors.standardbio.com or by contacting Standard BioTools’ Investor Relations department at investors@standardbio.com or at https://investors.somalogic.com or by contacting SomaLogic Investor Relations at investors@somalogic.com.

No Offer or Solicitation

This Current Report on Form 8-K and the information contained herein shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

Forward-Looking Statements

This Current Report on Form 8-K contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based upon current plans, estimates and expectations of the management of Standard BioTools and SomaLogic that are subject to various risks and uncertainties that could cause actual results to differ materially from such statements, many of which are beyond the control of Standard BioTools and SomaLogic. All statements other than statements of historical fact (including statements containing the words “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) are statements that could be deemed forward-looking statements, although not all forward- looking statements contain these identifying words. Readers should not place undue reliance on these forward-looking statements. Forward-looking statements may include statements regarding the expected timing of the closing of the Merger; the ability of the parties to complete the Merger considering the various closing conditions; and any assumptions underlying any of the foregoing. Statements regarding future events are based on the parties’ current expectations and are necessarily subject to associated risks related to, among other things, (i) the risk that the Merger may not be completed in a timely manner or at all, which may adversely affect Standard BioTools’ and SomaLogic’s businesses and the price of their respective securities; (ii) uncertainties as to the timing of the consummation of the Merger and the potential failure to satisfy the conditions to the consummation of the Merger, including obtaining stockholder and regulatory approvals; (iii) the Merger may involve unexpected costs, liabilities or delays; (iv) the effect of the announcement, pendency or completion of the Merger on the ability of Standard BioTools or SomaLogic to retain and hire key personnel and maintain relationships with customers, suppliers and others with whom Standard BioTools or SomaLogic does business, or on Standard BioTools’ or SomaLogic’s operating results and business generally; (v) Standard BioTools’ or SomaLogic’s respective businesses may suffer as a result of uncertainty surrounding the Merger and disruption of management’s attention due to the Merger; (vi) the outcome of any legal proceedings related to the Merger or otherwise, or the impact of the Merger thereupon; (vii) Standard BioTools or SomaLogic may be adversely affected by other economic, business and/or competitive factors, (viii) the occurrence of any event, change or other circumstances that could give rise to the termination of the Merger agreement and the Merger; (ix) restrictions during the pendency of the Merger that may impact Standard BioTools’ or SomaLogic’s ability to pursue certain business opportunities or strategic transactions; (x) the risk that Standard BioTools or SomaLogic may be unable to obtain governmental and regulatory approvals required for the Merger, or that required governmental and regulatory approvals may delay the consummation of the Merger or result in the imposition of conditions that could reduce the anticipated benefits from the Merger or cause the parties to abandon the Merger; (xi) risks that the anticipated benefits of the Merger or other commercial opportunities may otherwise not be fully realized or may take longer to realize than expected; (xii) the impact of legislative, regulatory, economic, competitive and technological changes; (xiii) risks relating to the value of the Standard BioTools shares to be issued in the Merger; (xiv) the risk that post-closing integration of the Merger may not occur as anticipated or the combined company may not be able to achieve the benefits expected from the Merger, as well as the risk of potential delays, challenges and expenses associated with integrating the combined company’s existing businesses; (xv) exposure to inflation, currency rate and interest rate fluctuations, as well as fluctuations in the market price of Standard BioTools’ and SomaLogic’s traded securities; (xvi) the lingering effects of the COVID-19 pandemic on Standard BioTools’ and SomaLogic’s industry and individual companies, including on counterparties, the supply chain, the execution of research and development programs, access to financing and the allocation of government resources; (xvii) the ability of Standard BioTools or SomaLogic to protect and enforce intellectual property rights; and (xviii) the unpredictability and severity of catastrophic events, including, but not limited to, acts of terrorism or outbreak of war or hostilities, as well as Standard BioTools’ and SomaLogic’s response to any of the aforementioned factors. Therefore, actual results may differ materially and adversely from those expressed in any forward-looking statements. For information regarding other related risks, see the “Risk Factors” section of Standard BioTools’ most recent quarterly report on Form 10-Q filed with the SEC on November 7, 2023, on its most recent annual report on Form 10-K filed with the SEC on March 14, 2023 and in Standard BioTools’ other filings with the SEC, as well as the “Risk Factors” section of SomaLogic’s most recent quarterly report on Form 10-Q filed with the SEC on November 8, 2023, on its most recent annual report on Form 10-K filed with the SEC on March 28, 2023 and in SomaLogic’s other filings with the SEC. The risks and uncertainties described above and in the SEC filings cited above are not exclusive and further information concerning Standard BioTools and SomaLogic and their respective businesses, including factors that potentially could materially affect their respective businesses, financial conditions or operating results, may emerge from time to time. Readers are urged to consider these factors carefully in evaluating these forward-looking statements, and not to place undue reliance on any forward-looking statements. Any such forward-looking statements represent management’s reasonable estimates and beliefs as of the date of this Current Report on Form 8- K. While Standard BioTools and SomaLogic may elect to update such forward-looking statements at some point in the future, they disclaim any obligation to do so, other than as may be required by law, even if subsequent events cause their views to change.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: December 26, 2023	SOMALOGIC, INC.

	By:	/s/ Ruben Gutierrez
	Name:	Ruben Gutierrez
	Title:	General Counsel

EX-99.1 2 tm2333732d1_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

FOR IMMEDIATE RELEASE

SomaLogic Issues Statement Correcting Madryn Asset Management’s Misleading Disclosure

SomaLogic Publishes Key Correspondence from LabCorp CEO Omitted by Madryn in its Attempt to Undermine Confidence in SomaLogic’s Thorough Strategic Process

Reiterates Value-Maximizing Transaction with Standard BioTools is in Best Interests of All Stockholders

BOULDER, Colo., Dec. 26, 2023 – SomaLogic, Inc. (Nasdaq: SLGC), a leader in proteomics technology, today issued the following statement in response to a press release issued by Madryn Asset Management, LP (“Madryn”) on December 26, 2023, regarding the pending merger with Standard BioTools (Nasdaq: LAB):

On Christmas Eve (December 24, 2023), Madryn resorted to manufacturing rumors of a third party’s interest in SomaLogic as its latest attempt to stand in the way of a Board-approved transaction. Madryn is using desperate tactics and misleading information in a last-ditch effort to undermine confidence in SomaLogic’s thorough strategic process and interfere with the resulting value-maximizing transaction between SomaLogic and Standard BioTools.

Madryn did not publish the response email from Adam Schecter, Chairman and CEO of LabCorp (NYSE: LH), which makes clear there is no substance to Madryn’s claims. Since the announcement of its pending merger with Standard BioTools, SomaLogic has not received any indication of interest or proposal from LabCorp or any other party with respect to a potential alternative transaction. The correspondence that occurred on Christmas Eve between Avinash Amin, Managing Director at Madryn, Adam Taich, SomaLogic’s Interim CEO, and Mr. Schecter and Garheng Kong, Lead Independent Director of LabCorp is laid out below.

·

At 9:53 a.m. ET on Christmas Eve, Mr. Amin sent an email to Mr. Taich, copying Messrs. Schecter and Kong, claiming that LabCorp was “interested in exploring strategic opportunities with SomaLogic.”

·

Following Mr. Amin’s email, SomaLogic did not receive correspondence in response from LabCorp.

·

At 5:43 p.m. ET that same day, Mr. Taich responded to Mr. Amin’s email seeking confirmation from LabCorp that Mr. Amin and Madryn were authorized to speak on behalf of LabCorp. Mr. Taich also referred to the merger agreement between SomaLogic and Standard BioTools, which includes the terms and conditions governing engagement between SomaLogic and potential third parties like LabCorp.

·

Madryn omitted a key item from its disclosure: within 10 minutes of receiving Mr. Taich’s email response requesting clarification, Mr. Schecter sent the following message to Messrs. Taich, Amin and Kong, which reflects the entire contents of the email:

“Avi and Madryn Capital Management are not in any way authorized to speak on LabCorp’s behalf. I wish you all of the best. Happy holidays.”

·

Mr. Amin separately replied to confirm that he was not authorized to speak for LabCorp.

·

There has been no outreach or correspondence from LabCorp after it immediately notified SomaLogic that Mr. Amin was not speaking on LabCorp’s behalf and wishing the SomaLogic Board and Management team “all of the best.” As is customary, the parameters of engagement with potential third parties, like LabCorp, are prescribed under the terms of the merger agreement.

The fact that Madryn is leaving out key details and that its claims lack substance is another self-serving attempt to stop a value-maximizing outcome for SomaLogic stockholders. The transaction with Standard BioTools is the result of a thorough, independent and deliberative Board process. SomaLogic publicly announced the initiation of its strategic review process in March 2023, which has provided ample opportunity over the last ten months for any potential strategic or financial partner to emerge. Throughout this process, the SomaLogic Board engaged with 16 parties to solicit potential interest in a transaction, but none expressed any actionable indication of interest and only one other than Standard BioTools entered into an NDA. Any interested party, particularly a large, sophisticated publicly traded company like LabCorp, had every opportunity to reach out directly to SomaLogic (rather than through Madryn) at any point in this public process beginning March 2023 and certainly prior to Christmas Eve, and certainly had the ability to be advised by its counsel as to the rules set forth in the merger agreement for any discussions or proposal. These merger agreement provisions are highly customary for a strategic transaction involving a publicly traded company, and do not permit solicitation of proposals by SomaLogic.

Notably, Institutional Shareholder Services (“ISS”), a leading independent proxy advisory firm, commented in its recommendation that SomaLogic stockholders vote “FOR” the merger that “…hopes of a potential buyer emerging in the medium term seem misplaced: SLGC has arguably been in play since March, when its CEO departed, leaving the company under interim management and a depressed share price, and the company publicly announced [SomaLogic] was pursuing strategic options. Despite these factors, and the possibility that the Olink deal may have subsequently increased interest in proteomics assets, no competing bidders have emerged, even though the board retains the ability to consider superior offers.”¹

The SomaLogic Board remains committed to acting in the best interests of all SomaLogic stockholders, and believes that the value-maximizing transaction with Standard BioTools is the best path forward for the Company and its stockholders. Madryn's criticisms of the transaction are without merit and continue to reflect their own self-interest. SomaLogic urges all stockholders to protect the value of their investment by voting “FOR” the transaction with Standard BioTools on the SomaLogic proxy card today. SomaLogic stockholders are advised to discard any green proxy cards they receive from Madryn.

¹Permission to use quotes neither sought nor obtained.

The response omitted by Madryn from Mr. Schecter is inserted below:

From: Schechter, Adam <[]>
Sent: Sunday, December 24, 2023 5:52 PM
To: Adam Taich <[]>
Cc: Avinash Amin <[]>; Garheng Kong <[]>; Troy Cox <[]>; Tom Carey <[]>; Tycho Peterson <[]>; Jason Ryan <[]>; Ruben Gutierrez <[]>; Ethan Skerry <[]>; van der Vaart, Sandra <[]>
Subject: RE: Introduction of Adam Taich to Adam Schecter, CEO of LabCorp

** EXTERNAL EMAIL **

Hi Adam,

Avi and Madryn Capital Management are not in any way authorized to speak on LabCorp’s behalf. I wish you all of the best. Happy holidays.

Adam

Adam Schechter

Chairman and CEO of Labcorp

labcorp.com

On Dec 24, 2023, at 5:43 PM, Adam Taich <[]> wrote:

EXTERNAL: This email originated from outside of the organization. Do not click any links or open any attachments unless you trust the sender and know the content is safe.

Dear Avi,

I have copied the members of our board you emailed today in the interest of providing visibility. Our merger agreement with Standard, which is publicly available, contains customary terms that provide the rules governing discussions of alternative proposals. These rules prohibit SomaLogic from soliciting acquisition proposals, or discussing proposals that do not meet the requirements of the merger agreement, and requires us to notify Standard if we receive any inquiries that could reasonably be expected to lead to an acquisition proposal. Your email implies that you are speaking on behalf of LabCorp. In order to ensure we are able to comply with our obligations under the merger agreement, I request that Adam Schecter and / or Garheng Kong confirm that Avi and Madryn Capital Management are authorized to speak on their and LabCorp’s behalf and, further, clarify their intent in authorizing your email.

Best regards,

Adam

From: Avinash Amin <[] >
Date: Sunday, December 24, 2023 at 9:53 AM
To: Adam Taich <[]>
Cc: Adam Schechter <[]>, Garheng Kong <[]>
Subject: Introduction of Adam Taich to Adam Schecter, CEO of LabCorp

CAUTION: External Email – use care with links or attachments.

Adam,

I would like to introduce you to Adam Schecter, CEO of LabCorp, and Garheng Kong MD, PhD, lead independent director of LabCorp, who are interested in exploring strategic opportunities with SomaLogic.

As you know we are against the current proposed merger with Standard Biotools and believe any opportunities with other strategics, including LabCorp, should be thoroughly explored, vetted, and disclosed to shareholders in advance of any vote on the Standard Biotools merger, which we view to be value destructive and rife with conflicts, as we have repeatedly stated in public.

Kind regards,

Avi

Avinash Amin, M.D.

Managing Partner

Madryn Asset Management, LP

330 Madison, 33^rd Floor

New York, NY 10017

E: []

D: []

M: []

The Company urges all stockholders to vote “FOR” the value maximizing transaction on the SomaLogic proxy card today. A special meeting of SomaLogic stockholders is scheduled to be held virtually in connection with the proposed merger on January 4, 2024, at 12 p.m. ET (10:00 a.m. MT / 9:00 a.m. PT).

SomaLogic stockholders who need assistance voting or have questions regarding the Special Meeting may contact SomaLogic’s proxy solicitor, Morrow Sodali LLC, at (800) 662-5200.

The merger remains on track to close in the first quarter of 2024, subject to approval by SomaLogic and Standard BioTools stockholders and satisfaction of other customary closing conditions.

About SomaLogic

SomaLogic is catalyzing drug research and development and biomarker identification as a global leader in proteomics technology. With a single 55 microliter plasma or serum sample, SomaLogic can run 11,000 protein measurements, covering more than a third of the approximately 20,000 proteins in the human body. For more than 20 years SomaLogic has supported pharmaceutical companies, and academic and contract research organizations who rely on the Company’s protein detection and analysis technologies to fuel drug, disease, and treatment discoveries in such areas as oncology, diabetes, and cardiovascular, liver and metabolic diseases. Find out more at somalogic.com and follow @somalogic on LinkedIn.

Additional Information and Where to Find It

In connection with the merger and required stockholder approval, Standard BioTools filed with the U.S. Securities and Exchange Commission (the “SEC”) a registration statement on Form S-4, as amended (the “Form S-4”), which was declared effective by the SEC on December 1, 2023. The Form S-4 includes a definitive joint proxy statement of Standard BioTools and SomaLogic and also constitutes a final prospectus of Standard BioTools. The definitive joint proxy statement was mailed or otherwise made available to stockholders of Standard BioTools and SomaLogic on or about December 4, 2023. Standard BioTools’ and SomaLogic’s stockholders are urged to carefully read the joint proxy statement/prospectus (including all amendments, supplements and any documents incorporated by reference therein) and other relevant materials filed or to be filed with the SEC and in their entirety because they contain important information about the merger and the parties to the merger. Investors and stockholders may obtain free copies of these documents and other documents filed with the SEC at its website at http://www.sec.gov. In addition, investors may obtain free copies of the documents filed with the SEC by Standard BioTools at http://investors.standardbio.com or contacting Standard BioTools’ Investor Relations department at investors@standardbio.com or at https://investors.somalogic.com or by contacting SomaLogic Investor Relations at investors@somalogic.com.

Participants in the Solicitation

Standard BioTools, SomaLogic and each of their respective executive officers and directors may be deemed to be participants in the solicitation of proxies from Standard BioTools and SomaLogic’s stockholders with respect to the merger. Information about Standard BioTools’ directors and executive officers, including their ownership of Standard BioTools’ securities, is set forth in the joint proxy statement/prospectus, Standard BioTools’ proxy statement for its 2023 Annual Meeting of Stockholders, which was filed with the SEC on April 28, 2023, Current Reports on Form 8-K, which were filed with the SEC on May 3, 2023, May 15, 2023, June 16, 2023 and July 28, 2023, and Standard BioTools’ other filings with the SEC. Information concerning SomaLogic’s directors and executive officers, including their ownership of SomaLogic securities, is set forth in the joint proxy statement/prospectus, SomaLogic’s proxy statement for its 2023 Annual Meeting of Stockholders, which was filed with the SEC on April 25, 2023, Current Reports on Form 8-K, which were filed with the SEC on June 6, 2023, as amended on June 14, 2023, June 9, 2023, October 4, 2023 and December 12, 2023, and SomaLogic’s other filings with the SEC. Investors may obtain more detailed information regarding the direct and indirect interests of Standard BioTools and its respective executive officers and directors in the merger, which may be different than those of Standard BioTools’ stockholders generally, by reading the definitive proxy statements regarding the merger, which have been filed with the SEC. These documents are available free of charge at the SEC’s website at www.sec.gov, at http://investors.standardbio.com or by contacting Standard BioTools’ Investor Relations department at investors@standardbio.com or at https://investors.somalogic.com or by contacting SomaLogic Investor Relations at investors@somalogic.com.

No Offer or Solicitation

This press release and the information contained herein shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based upon current plans, estimates and expectations of the management of Standard BioTools and SomaLogic that are subject to various risks and uncertainties that could cause actual results to differ materially from such statements, many of which are beyond the control of Standard BioTools and SomaLogic. All statements other than statements of historical fact (including statements containing the words “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) are statements that could be deemed forward-looking statements, although not all forward-looking statements contain these identifying words. Readers should not place undue reliance on these forward-looking statements. Forward-looking statements may include statements regarding the expected timing of the closing of the merger; the ability of the parties to complete the merger considering the various closing conditions; and any assumptions underlying any of the foregoing. Statements regarding future events are based on the parties’ current expectations and are necessarily subject to associated risks related to, among other things, (i) the risk that the Merger may not be completed in a timely manner or at all, which may adversely affect Standard BioTools’ and SomaLogic’s businesses and the price of their respective securities; (ii) uncertainties as to the timing of the consummation of the merger and the potential failure to satisfy the conditions to the consummation of the merger, including obtaining stockholder and regulatory approvals; (iii) the merger may involve unexpected costs, liabilities or delays; (iv) the effect of the announcement, pendency or completion of the merger on the ability of Standard BioTools or SomaLogic to retain and hire key personnel and maintain relationships with customers, suppliers and others with whom Standard BioTools or SomaLogic does business, or on Standard BioTools’ or SomaLogic’s operating results and business generally; (v) Standard BioTools’ or SomaLogic’s respective businesses may suffer as a result of uncertainty surrounding the merger and disruption of management’s attention due to the merger; (vi) the outcome of any legal proceedings related to the merger or otherwise, or the impact of the merger thereupon; (vii) Standard BioTools or SomaLogic may be adversely affected by other economic, business and/or competitive factors, (viii) the occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement and the merger; (ix) restrictions during the pendency of the merger that may impact Standard BioTools’ or SomaLogic’s ability to pursue certain business opportunities or strategic transactions; (x) the risk that Standard BioTools or SomaLogic may be unable to obtain governmental and regulatory approvals required for the merger, or that required governmental and regulatory approvals may delay the consummation of the merger or result in the imposition of conditions that could reduce the anticipated benefits from the merger or cause the parties to abandon the merger; (xi) risks that the anticipated benefits of the merger or other commercial opportunities may otherwise not be fully realized or may take longer to realize than expected; (xii) the impact of legislative, regulatory, economic, competitive and technological changes; (xiii) risks relating to the value of the Standard BioTools shares to be issued in the merger; (xiv) the risk that post-closing integration of the merger may not occur as anticipated or the combined company may not be able to achieve the benefits expected from the merger, as well as the risk of potential delays, challenges and expenses associated with integrating the combined company’s existing businesses; (xv) exposure to inflation, currency rate and interest rate fluctuations, as well as fluctuations in the market price of Standard BioTools’ and SomaLogic’s traded securities; (xvi) the lingering effects of the COVID-19 pandemic on Standard BioTools’ and SomaLogic’s industry and individual companies, including on counterparties, the supply chain, the execution of research and development programs, access to financing and the allocation of government resources; (xvii) the ability of Standard BioTools or SomaLogic to protect and enforce intellectual property rights; and (xviii) the unpredictability and severity of catastrophic events, including, but not limited to, acts of terrorism or outbreak of war or hostilities, as well as Standard BioTools’ and SomaLogic’s response to any of the aforementioned factors. Therefore, actual results may differ materially and adversely from those expressed in any forward-looking statements. For information regarding other related risks, see the “Risk Factors” section of Standard BioTools’ most recent quarterly report on Form 10-Q filed with the SEC on November 7, 2023, on its most recent annual report on Form 10-K filed with the SEC on March 14, 2023 and in Standard BioTools’ other filings with the SEC, as well as the “Risk Factors” section of SomaLogic’s most recent quarterly report on Form 10-Q filed with the SEC on November 8, 2023, on its most recent annual report on Form 10-K filed with the SEC on March 28, 2023 and in SomaLogic’s other filings with the SEC. The risks and uncertainties described above and in the SEC filings cited above are not exclusive and further information concerning Standard BioTools and SomaLogic and their respective businesses, including factors that potentially could materially affect their respective businesses, financial conditions or operating results, may emerge from time to time. Readers are urged to consider these factors carefully in evaluating these forward-looking statements, and not to place undue reliance on any forward-looking statements. Any such forward-looking statements represent management’s reasonable estimates and beliefs as of the date of this press release. While Standard BioTools and SomaLogic may elect to update such forward-looking statements at some point in the future, they disclaim any obligation to do so, other than as may be required by law, even if subsequent events cause their views to change.

Contacts

Investors

Marissa Bych
Gilmartin Group LLC
investors@somalogic.com

Media

Lyle Weston / Carly King

Joele Frank, Wilkinson Brimmer Katcher

(212) 355-4449

EX-101.SCH 3 slgc-20231226.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 slgc-20231226_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 slgc-20231226_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Class of Stock [Axis] Common Class A [Member] Warrant [Member] Statement [Table] Document Information [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 slgc-20231226_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 R1.htm IDEA: XBRL DOCUMENT

Cover	Dec. 26, 2023
Document Information [Line Items]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Dec. 26, 2023
Entity File Number	001-40090
Entity Registrant Name	SomaLogic, Inc.
Entity Central Index Key	0001837412
Entity Tax Identification Number	85-4298912
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	2945 Wilderness Place
Entity Address, City or Town	Boulder
Entity Address, State or Province	CO
Entity Address, Postal Zip Code	80301
City Area Code	303
Local Phone Number	625-9000
Written Communications	true
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Common Class A [Member]
Document Information [Line Items]
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	SLGC
Security Exchange Name	NASDAQ
Warrant [Member]
Document Information [Line Items]
Title of 12(b) Security	Warrants, each exercisable for one share of Common Stock at an exercise price of $11.50 per share
Trading Symbol	SLGCW
Security Exchange Name	NASDAQ

XML 8 tm2333732d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001837412 2023-12-26 2023-12-26 0001837412 us-gaap:CommonClassAMember 2023-12-26 2023-12-26 0001837412 us-gaap:WarrantMember 2023-12-26 2023-12-26 iso4217:USD shares iso4217:USD shares false 0001837412 8-K 2023-12-26 SomaLogic, Inc. DE 001-40090 85-4298912 2945 Wilderness Place Boulder CO 80301 303 625-9000 true false false false Common Stock, par value $0.0001 per share SLGC NASDAQ Warrants, each exercisable for one share of Common Stock at an exercise price of $11.50 per share SLGCW NASDAQ true false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( $")FE<'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " ! B9I7<:#40.X K @ $0 &1O8U!R;W!S+V-O&ULS9+/ M2L0P$(=?17)OITVQ8.CFLN))07!!\1:2V=U@\X=DI-VWMZV[740?P&-F?OGF M&YA.1Z%#PN<4(B:RF&]&U_LL=-RP(U$4 %D?T:E<3@D_-?R,%CJAHI#.>*-7?/Q,_0(S&K!'AYXRU&4-3,X3 MXVGL.[@"9AAA621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M $")FE>EK,84'04 /H5 8 >&PO=V]R:W-H965T&UL MM9A=;^)&%(;O^RM&=%6U4A+L 1)("1(AR3;:?-"0;:2N>C'8!QBM[?'.C /Y M]SUCB$VSYIA&VIO$-CZO'Y_/\?272G\U"P#+5G&4F+/&PMKTM-DTP0)B88Y4 M"@G^,E,Z%A9/];QI4@TBS(WBJ,D][[@9"YDT!OW\VE@/^BJSD4Q@K)G)XECH MEW.(U/*LX3=>+SS(^<*Z"\U!/Q5SF(#]G(XUGC4+E5#&D!BI$J9A=M88^J?G M+>X,\CO^DK T6\?,O'V\:OZ5?[R^#)386"DHB<9VL59H]M@(7 =\8Y(YHKA^44UX(*P9]K99,N[M1 MS1WDKYI;(YQ,7%0F5N.O$NWL8*2>0?>;%J7Z[5VZ:D@PUA;=IVL,\U%[,L-WL6N+<3FGRK$M62[6M*E M\ZE)10!G#PR"1EF8Z5?:I1>\ZHNL8X+ MM&-2\#*QTKZP*QD!N\OB:76RTQJ>YQ^V/:_G$3PG!<_)/CP/,)?&:H$^NQ-Q MI:-HG8F*Q8V:R^ 2R8X(LBZ!5EW'[(1QE&+"%5#6+%/\%+%1BMYZ+!NZZ3M M9O'7 AH_6'-U3:.4L\.EF_A9MK(S%.OY;IKMSCU;L>BW/ MI]C*^>#3;3V/X!!7C;M1:(&61PT#OYP&/MW*;U2 /ADO5$*-@QJ18]XY[&&3 MHXC*>>#3C?Q)2VLA0INII**%K,[(\BOG@$^W[XF*9""M3.;L%K-; M2Q%5XM J=6L+OQP /MVOQQH. _0.8'FMEURXZ@'-[F>S'>&C]>K(>-GZ.=V< MOR.[-B9#LCK &ME:P++M\[W:_F4,>N[B^1$5[,+E6BJ2RLE>(UB39'QKO5_3 MX]UG&83L3F$\%?ML@-D%L,N5=;X+V2.NC8S,Y_QZ45D)2S^CUH]EV^4PX?0S\JJ@1 MNAM.+H9_4DSE&.'T '@2.O^^(8N%E'AOXI63A?=^0+&0T^6]VP[ES&G1P^%_ M%$N-TB9 N%0$$2P8K$ 'TH@IRJ,WF%LBY;7B'K9I@'EA,6&92%[O!Y9J&>0W M??#]HXZW5Y&URA'6HB=.?9'5"+@B>Z)0RIG5HN?)_E56([2[RII;.WEN5_16 MN,%M6 0S5/*.3K#_Z?5&X_K$JC3?W)LJ:U6<'RY X.K#W8"_SY2RKR=NO[#8 M[AW\"U!+ P04 " ! B9I7GZ ;\+$" #B# #0 'AL+W-T>6QEO%DN7/ZZZ>S;"=I M=67=A['-HN6/O.-%Q[ MI#)6,>=56R=M8SDK6W!2,EG>W&2)8D+38JT[=:=<2PZFTVY#;VA2K"NCSY:4 M!H-?RA0GCTQNZ)9)L;=B6,N4D*=@7H+A8*2QQ'DJ?$,78&F? KP(&K XU7=>&18/QA<0&>7=J?$,:\M. MB^4M/3L,/S[)WMB2VSG-@DZF8BUY!72LJ(_PZTR3 .B<45XH!:N-9@.'R6,4 M?-@#E_(!6OBMNHK=5R3TXE,);2"PU4GTA$8QA D*Q+^,%F)?A+W]K;"D$8_& M?>S\;O2@?^^,X_>65Z(?]+Z:\V/1%WATUC3R]$&*6BL>]O[+"8LUF_S(T5CQ MY+/!I!R\@5M*'KEUXG!I^6%9L^.]FZ:IKW#.RW^0\Y^M<\TUMTQ>DO:C_S=7 M^2V,D_'T7!S1JP,Z6PEY7>>9 ]IV03NA1.XJRY/K%.?7A'=O["_PJ MOE]?\HIUTNUF<$//\A=>BD[E\ZI[J,NXZBQ_AOMHD\%G'!QR>(W?#$T% M^@2O&+(=/EB>N$_NG_A.\SQ-LPRKZ'8;9;#%ZI9E\!>/AG$##RP/9'I;K?%N MXQ/R^AQ@/7UM0K"=XI.([12O-2#QNH%'GL>[C>4!#ZP+V.Q _G@>F*FX3YI" M5S%NV G&D3S'$)C%^(QF&5*=##[Q_F"G)$WS/(X %F>0IA@"IQ%', ; 4/2 M='@//GL?)=-[*CG_5U/\!%!+ P04 " ! B9I7EXJ[', 3 @ "P M %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6= MOZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6' MTD!$VV-#L%HL/D N&6:WO606IW.D5XA-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T M>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0 ( $")FE>JQ"(6,P$ M "(" / >&PO=V]R:V)O;VLN>&ULC5'1;L(P#/R5*A^P%K0A#5%>0-N0 MI@V-B??0NM0BB2O'A8VOG]NJ&M)>]I31=B;FJ19IZF ML:C!VWA'#02=5,3>BD(^IK%AL&6L <2[=)IEL]1;#&:Y&+6VG-X"$B@$*2C9 M$7N$2_R==S Y8\0#.I3OW/1W!R;Q&-#C%B/%*0:S;%4S.Y68R M#/; @L4?>M>9_+2'V#-B#Q]6C>1FEJE@A1REW^CUK7H\@RX/J!5Z0B? :ROP MS-0V&(Z=C*9(;V+T/8SG4.*<_U,C5146L*:B]1!DZ)'!=09#K+&))@G60VY6 M= ;N\N@#FW+()FKJIBF>HPYX4P[V1D\E5!B@?%.9J+SV4VPYZ8Y>9WK_,'G4 M'EKG5LJ]AU>RY1AQ_)[E#U!+ P04 " ! B9I7)!Z;HJT #X 0 &@ M 'AL+U]R96QS+W=O[IFBG#S^0W1UW6E\./VR M./ /,+Q=Z*E%9"E*%1KD3,)HMC;!4N++3):BJ#(9BBJ6<%H@XLD@;6E6?;!/ M3K3G>1,)KM\,<'AT_@%02P,$% @ 0(F:5V60>9(9 0 SP, M !, !;0V]N=&5N=%]4>7!E&ULK9--3L,P$(6O$F5;)2XL6*"F&V + M77 !8T\:J_Z39UK2VS-.VDJ@$A6%3:QXWKS/GI>LWH\1L.B=]=B4'5%\% )5 M!TYB'2)XKK0A.4G\FK8B2K636Q#WR^6#4,$3>*HH>Y3KU3.T.EY&TWP M39G 8ED\C<+,:DH9HS5*$M?%P>L?E.I$J+EST&!G(BY84(JKA%SY'7#J>SM M2D9#L9&)7J5CE>BM0#I:P'K:XLH90]L:!3JHO>.6&F,"J;$#(&?KT70Q32:> M,(S/N]G\P68*R,I-"A$YL01_QYTCR=U59"-(9*:O>"&R]>S[04Y;@[Z1S>/] M#&DWY(%B6.;/^'O&%_\;SO$1PNZ_/[&\UDX:?^:+X3]>?P%02P$"% ,4 M" ! B9I7!T%-8H$ "Q $ @ $ 9&]C4')O<',O M87!P+GAM;%!+ 0(4 Q0 ( $")FE=QH-1 [@ "L" 1 M " :\ !D;V-097)PC M$ 8 )PG 3 " &UL M4$L! A0#% @ 0(F:5Z6LQA0=!0 ^A4 !@ ("!#0@ M 'AL+W=O?H!OP ML0( .(, - " 6 - !X;"]S='EL97,N>&UL4$L! A0# M% @ 0(F:5Y>*NQS $P( L ( !/! %]R96QS M+RYR96QS4$L! A0#% @ 0(F:5ZK$(A8S 0 (@( \ M ( !)1$ 'AL+W=O7!E&UL4$L%!@ ) D /@( +04 ! $! end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.4 html 3 23 1 false 2 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://somalogic/role/Cover Cover Cover 1 false false All Reports Book All Reports slgc-20231226.xsd slgc-20231226_def.xml slgc-20231226_lab.xml slgc-20231226_pre.xml tm2333732d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2333732d1_8k.htm": { "nsprefix": "SLGC", "nsuri": "http://somalogic/20231226", "dts": { "schema": { "local": [ "slgc-20231226.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "definitionLink": { "local": [ "slgc-20231226_def.xml" ] }, "labelLink": { "local": [ "slgc-20231226_lab.xml" ] }, "presentationLink": { "local": [ "slgc-20231226_pre.xml" ] }, "inline": { "local": [ "tm2333732d1_8k.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 2, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 3, "entityCount": 1, "segmentCount": 2, "elementCount": 65, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 26 }, "report": { "R1": { "role": "http://somalogic/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-12-26", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2333732d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-26", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2333732d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://somalogic/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantMember", "presentation": [ "http://somalogic/role/Cover" ], "lang": { "en-us": { "role": { "label": "Warrant [Member]" } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://somalogic/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://somalogic/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://somalogic/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://somalogic/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://somalogic/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://somalogic/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://somalogic/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://somalogic/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://somalogic/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://somalogic/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://somalogic/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://somalogic/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://somalogic/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://somalogic/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://somalogic/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://somalogic/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://somalogic/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://somalogic/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://somalogic/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://somalogic/role/Cover" ], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://somalogic/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://somalogic/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://somalogic/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://somalogic/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://somalogic/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://somalogic/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://somalogic/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://somalogic/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://somalogic/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://somalogic/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "us-gaap_CommonClassAMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonClassAMember", "presentation": [ "http://somalogic/role/Cover" ], "lang": { "en-us": { "role": { "label": "Common Class A [Member]" } } }, "auth_ref": [] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://somalogic/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://somalogic/role/Cover" ], "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://somalogic/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://somalogic/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://somalogic/role/Cover" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "auth_ref": [] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://somalogic/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://somalogic/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://somalogic/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://somalogic/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://somalogic/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://somalogic/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://somalogic/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://somalogic/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://somalogic/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://somalogic/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://somalogic/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://somalogic/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://somalogic/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://somalogic/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://somalogic/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://somalogic/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://somalogic/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://somalogic/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://somalogic/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationLineItems", "presentation": [ "http://somalogic/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://somalogic/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://somalogic/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://somalogic/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://somalogic/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://somalogic/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://somalogic/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001104659-23-129259-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-129259-xbrl.zip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end